About Us

At Adiso, we create medicines to treat inflammatory diseases, to improve the lives of patients and their families. We believe that current therapeutic approaches are often inadequate to halt disease progression or run the risk of burdening the patient with significant safety concerns.

To tackle these challenges, we are advancing an innovative, multi-modal pipeline of small molecules and single strain live biotherapeutic products all with novel mechanisms of action. Our approach is scientifically and clinically cutting edge in that it is both targeted and locally acting at the site of inflammation.

ADS051 is a first-in-class modulator of neutrophil activity which is nearing completion of a Ph1b study in moderate-to-severe ulcerative colitis (UC). Adiso is also developing ADS032, a novel small molecule that acts as a dual inflammasome inhibitor (NLRP3 & NLRP1), it has entered IND enabling studies for the treatment of respiratory and dermal inflammation. ADS024 (SS-LBP) has just completed a Phase 1b study for the prevention of recurrent CDI and is Phase 2 ready for our moderate ulcerative colitis (UC) trial.

Team & Founders

Leadership Team

Scott Megaffin
Chief Executive Officer

Jennifer Locke
Chief Operating & Business Officer

Bharat Dixit, PhD
Chief Technology Officer

Renu Gupta, M.D.
Chief Medical Officer

Srikar Guntaka, M.D.
Medical Director

Jillian Chapas-Reed
Head of Clinical Operations

Ashley Mansell, PhD
Head of Translational Science

Laurent Chesnel, PhD

Laurent Chesnel, PhD
Head of Research & Development

Chris Murphy, PhD
Head of Research & Development

Shannon Foley
Head of Finance

Discovery Team

Small Molecule Modulator of Neutrophil Trafficking and Activation

Discovery

IND Enabling

Phase 1

Phase 2

Phase 3

ADS051

Ulcerative Colitis

ADS051 is an oral, gut-restricted, small molecule modulator of neutrophil trafficking and activation for the treatment of ulcerative colitis. ADS051 blocks MRP2-mediated neutrophil trafficking into and FRP1-mediated neutrophil activation within the colonic lumen. Unlike currently available therapies, this addresses neutrophil-mediated tissue damage, a hallmark of UC pathology. In a healthy volunteer study, ADS051 was safe and well-tolerated and restricted to the gut with limited systemic exposure.

First-In-Class Small Molecule Inhibitor of the NLRP1 and 3 Inflammasomes

Discovery

IND Enabling

Phase 1

Phase 2

Phase 3

ADS032

Respiratory Inflammation

ADS032 is a novel small molecule inhibitor that blocks two types of inflammasomes simultaneously, NLRP1 and NLRP3 – the innate immune system’s receptors and first line sensors of pathogens and other danger signals. Chronic activation of NLRP1 and NLPR3 is directly implicated in a wide
range of inflammation-triggered conditions across multiple organ systems. By targeting both NLRP3 and NLRP1, ADS032 may provide a comprehensive anti-inflammatory approach across a range of diseases.

Single Strain Live Biotherapeutic Product (SS-LBP) Platform

Discovery

IND Enabling

Phase 1

Phase 2

Phase 3

ADS024 CDI

Prevention of CDI Recurrence

ADS024 is an oral single strain live biotherapeutic product (SS-LBP). A naturally occurring live biotherapeutic product, ADS024 possesses a dual mechanism of action. It is bactericidal toward Clostridioides difficile and degrades Toxins A and B produced by C. difficile while maintaining other components of the microbiome. ADS024 is a single strain multimodal LBP and is manufactured from a pure, clonal bacterial cell bank, yielding a standardized lyophilized drug product eliminating the need to directly source from donor fecal material.

ADS024 UC

Ulcerative Colitis

ADS024 is an oral single strain live biotherapeutic product (SS-LBP). A naturally occurring live biotherapeutic product, ADS024 modulates inflammation as a single strain multimodal LBP and has been shown to reduce neutrophil trafficking through the colonic epithelium. ADS024 is manufactured from a pure, clonal bacterial cell bank, yielding a standardized lyophilized drug product eliminating the need to directly source from donor fecal material.

ADS00X

Neuroinflammation

ADS00X has demonstrated pre-clinical efficacy in the 3 models of neuroinflammatory disease. Adiso is pursuing confirmatory evidence which supports the impact of our SS-LBP products on the Gut-Brain Axis.

Contact Us